By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
The Best 15 Applications for Efficiency and Association - 2Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- 3From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous
- 4Am I a Summer, or is this a scam? What I learned from color analysis.
- 59 African migrants died in freezing temperatures near Morocco-Algeria border
- The Solution to Ecological Protection: Saving Nature for People in the future
- Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- IDF: Staying in West Bank refugee camps will quell lone-wolf terror
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- The Job of a Land Legal counselor in Property Exchanges
- The breakout star of NASA's Artemis 2 moon mission isn't an astronaut — it's the space toilet
- 10 Asian Countries Perfect for Solo Female Travelers
- We may have less control over how long we live than previously thought
